Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.05 is 42% below its 5-year average of 0.09, near the low end of its 5-year range (0.01–0.18).
As of the fiscal period ended Tuesday, June 30, 2026. 52.58% below its 12-month average of 0.11.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.05.
DEBT TO EQUITY RATIO
0.05
DEBT TO EQUITY RATIO AVG TTM
0.11
DEBT TO EQUITY RATIO AVG 3Y
0.12
DEBT TO EQUITY RATIO AVG 5Y
0.09
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-52.58%
CURRENT VS 3Y AVG
-55.32%
CURRENT VS 5Y AVG
-42.38%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.15
median of 414 covered companies
CURRENT VS SECTOR MEDIAN
-63.70%
vs the sector median at left
Aura Biosciences, Inc.
Market Cap
$643.37M
Debt to Equity Ratio
0.05
TTM Avg
0.11
3Y Avg
0.12
5Y Avg
0.09
Market Cap
$642.31M
Debt to Equity Ratio
0.00
TTM Avg
0.03
3Y Avg
0.06
5Y Avg
0.06
Market Cap
$637.59M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$675.41M
Debt to Equity Ratio
0.10
TTM Avg
0.04
3Y Avg
0.05
5Y Avg
0.04
Market Cap
$600.84M
Debt to Equity Ratio
N/A
TTM Avg
0.72
3Y Avg
2.89
5Y Avg
12.33
Market Cap
$596.36M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.05
Market Cap
$698.60M
Debt to Equity Ratio
0.00
TTM Avg
0.09
3Y Avg
0.09
5Y Avg
0.07
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $643.37M | 0.05 | 0.11 | 0.12 | 0.09 |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | 0.00 | 0.03 | 0.06 | 0.06 |
| Fulgent Genetics, Inc. (FLGT)vs › | $637.59M | 0.01 | 0.01 | 0.02 | 0.02 |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | 0.01 | 0.00 | 0.00 | 0.00 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.41M | 0.10 | 0.04 | 0.05 | 0.04 |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $600.84M | N/A | 0.72 | 2.89 | 12.33 |
| Annexon, Inc. (ANNX)vs › | $688.14M | 0.13 | 0.11 | 0.12 | 0.11 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | 0.00 | 0.01 | 0.01 | 0.05 |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | 0.00 | 0.09 | 0.09 | 0.07 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $579.88M | 0.28 | N/A | N/A | N/A |
Debt/Equity
0.05
Current Ratio
16.82
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.05 |
| 2026-03-31 | 0.16 |
| 2025-12-31 | 0.13 |
| 2025-09-30 | 0.11 |
| 2025-06-30 | 0.10 |
| 2025-03-31 | 0.14 |
| 2024-12-31 | 0.12 |
| 2024-09-30 | 0.11 |
| 2024-06-30 | 0.10 |
| 2024-03-31 | 0.09 |
| 2023-12-31 | 0.09 |
| 2023-09-30 | 0.13 |
| 2023-06-30 | 0.12 |
| 2023-03-31 | 0.11 |
| 2022-12-31 | 0.11 |
| 2022-09-30 | 0.18 |
| 2022-06-30 | 0.01 |
| 2022-03-31 | 0.01 |
| 2021-12-31 | 0.01 |
| 2021-09-30 | 0.02 |
| 2021-06-30 | 0.01 |
| 2021-03-31 | 0.01 |
| 2020-12-31 | 0.00 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
